Samarium(II) promoted stereoselective synthesis of antiproliferative cis-β-alkoxy-γ-alkyl-γ-lactones

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 1, 2007, Pages 18-21

  Donadel, Osvaldo J ^a,b   Martín, Tomás ^a,c   Martín, Víctor S ^a   Padrón, José M ^a,d  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

^c INSTITUTO DE PRODUCTOS NATURALES Y AGROBIOLOGÍA   (Spain)

^d Madrid Spain   (Spain)

Author keywords

Lactones; Anticancer drugs; Samarium(II) iodide; Solid tumors; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA LACTONE DERIVATIVE; LACTONE DERIVATIVE; SAMARIUM DIIODIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COLON CANCER; DRUG SYNTHESIS; GROWTH INHIBITION; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; SOLID TUMOR; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IODIDES; LACTONES; SAMARIUM; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845671140     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.005     Document Type: Article

References (33)

1. Picman A.K. Biochem. Syst. Ecol. 14 (1986) 255
2. Devon T.K., and Scott A.I. Handbook of Naturally Occurring Compounds 1 (1975), Academic, New York
3. Fischer N.H., Olivier E.J., and Fischer H.D. Fortschr. Chem. Org. Nat. 38 (1979) 47
4. Brown H.C., Kulkarni S.K., and Racherla U.S. J. Org. Chem. 59 (1994) 365
5. Rodríguez A.D., Piña I.C., and Barness C.L. J. Org. Chem. 60 (1995) 8096
6. Bandichhor R., Nosse B., and Reiser O. Top. Curr. Chem. 243 (2005) 43
7. Collins I. J. Chem. Soc. Perkin Trans. 1 (1999) 1377
8. Collins I. J. Chem. Soc. Perkin Trans. 1 (1998) 1869
9. Rodríguez C.M., Martín T., Ramírez M.A., and Martín V.S. J. Org. Chem. 59 (1994) 4461
10. For reports on the synthesis of cis-β,γ-disubstituted-γ-lactones, see:. Byström S., Högberg H.-E., and Norin T. Tetrahedron 37 (1981) 2249
11. Nubbemeyer U., Öhrlein R., Gonda J., Ernst B., and Bellus D. Angew. Chem., Int. Ed. Engl. 30 (1991) 1465
12. Ferreira J.T.B., Marques J.A., and Marino J.P. Tetrahedron: Asymmetry 5 (1994) 641
13. Brecht-Forster A., Fitremann J., and Renaud P. Helv. Chim. Acta 85 (2002) 3965
14. Wu Y., Shen X., Tang C.-J., Chen Z.-L., Hu Q., and Shi W. J. Org. Chem. 67 (2002) 3802
15. Doyle M.P., Zhou Q.-L., Dyatkin A.B., and Ruppar D.A. Tetrahedron Lett. 36 (1995) 7579
16. Fukuzawa S., Seki K., Tatsuzawa M., and Mutoh K. J. Am. Chem. Soc. 119 (1997) 1482
17. Kerrigan N.J., Hutchison P., Heightman C.T.D., and Procter D.J. Chem. Commun. (2003) 1402
18. Ramachandran P.V., Padiya K.J., Rauniyar V., Reddy M.V.R., and Brown H.C. Tetrahedron Lett. 45 (2004) 1015
19. Kagan, H.; Namy, J. L. In Lanthanides Chemistry and Use in Organic Synthesis, Ed. Kobayashi, S., Springer, Heidelberg, 1999, p. 155.
20. Edmonds D.J., Johnston D., and Procter D.J. Chem. Rev. 104 (2004) 3371
21. Fukuzawa S., Nakanishi A., Fujinami T., and Sakai S. Chem. Commun. (1986) 624
22. Otsubo K., Inanaga J., and Yamaguchi M. Tetrahedron Lett. 27 (1986) 5763
23. Fukuzawa S., Nakanishi A., Fujinami T., and Sakai S. J. Chem. Soc. Perkin Trans. 1 (1988) 1669
24. Kerrigan N.J., Upadhyay T., and Procter D.J. Tetrahedron Lett. 45 (2004) 9087
25. Donadel O.J., Martín T., Martín V.S., Villar J., and Padrón J.M. Bioorg. Med. Chem. Lett. 15 (2005) 3536
26. Padrón J.M., Tejedor D., Santos-Expósito A., García-Tellado F., Martín V.S., and Villar J. Bioorg. Med. Chem. Lett. 15 (2005) 2487
27. García C., Martín T., and Martín V.S. J. Org. Chem. 66 (2001) 1420
28. Martín T., Soler M.A., Betancort J.M., and Martín V.S. J. Org. Chem. 62 (1997) 1570
29. 4, filtered, and the solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (EtOAc/hexane, 1:9) to give γ-lactone 3.
30. 3): δ 14.1 (q), 22.6 (t), 24.9 (t), 25.0 (t), 25.1 (t), 25.6 (t), 28.4 (t), 28.6 (t), 29.1 (t), 29.2 (t), 29.4 (t), 29.5 (t), 31.7 (t), 35.6 (t), 36.0 (t), 37.2 (t), 67.3 (d), 70.4 (d), 72.8 (d), 74.3 (d), 74.5 (d), 75.7 (d), 83.0 (s), 84.3 (d), 84.4 (d), 175.2 (s).
31. 1H coupling constants.{A figure is presented}
32. 50) represent the drug concentration at which PG is +50, 0, and -50, respectively. Skehan P., Storeng P., Scudeiro D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107
33. Miranda P.O., Padrón J.M., Padrón J.I., Villar J., and Martín V.S. ChemMedChem 1 (2006) 323